Latest Generalised epilepsy Stories

2012-03-26 09:37:42

A new epilepsy gene for idiopathic epilepsy in Belgian Shepherds has been found in the canine chromosome 37. The research of Professor Hannes Lohi and his group conducted at the University of Helsinki and the Folkhälsan Research Center opens new avenues for the understanding of the genetic background of the most common canine epilepsies. The research also has an impact on the understanding of common epilepsies in humans. The research is published in the scientific journal PLoS...

2011-07-18 08:00:00

MAPLE GROVE, Minn., July 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for...

2011-01-25 01:22:00

HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial seizures in patients with...

2010-03-18 11:23:20

A recent study organized by Stanford University researchers found patients with refractory partial and secondarily generalized seizures had a reduction in seizures after deep brain stimulation. This multi-center clinical trial determined that the benefits of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE) persisted and by 2 years there was a 56% reduction in seizure frequency. Full findings of this study are available early online in Epilepsia, a journal published by...

2008-12-06 15:00:00

SEATTLE, Dec. 6 /PRNewswire-FirstCall/ -- Results from RESTORE 2, a placebo-controlled, Phase III study demonstrated that the investigational compound retigabine significantly reduced the number of seizures in adult patients with refractory partial-onset epilepsy when a 600 mg or 900 mg dose was added to a patient's current anti-epileptic drug (AED) therapy. Prior to enrollment in the retigabine clinical trials, patients were experiencing seizures despite taking stable doses of up to...

2008-11-20 19:35:58

The U.S. Food and Drug Administration has approved a new drug, rufinamide -- marketed as Banzel -- to treat severe epilepsy. The drug is to be used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome. This approval offers another treatment option for patients who suffer from these debilitating, severe seizures, Dr. Russell Katz of the FDA's Center for Drug Evaluation and Research said Thursday in a statement. Lennox-Gastaut syndrome is a severe form of epilepsy...

2008-09-15 18:00:37

Valeant Pharmaceuticals International (NYSE:VRX) announced today that clinical data for retigabine from the Phase III RESTORE program will be presented at the 8th European Congress on Epileptology, which will be held at the Berlin Internationales Congress Centrum (ICC) in Berlin, Germany, September 21-24, 2008. Please note the following events and their dates and times below: Event Date Time ------------------------ ---------------------...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.